# Sarim Khan

> Sarim Khan is co-founder and CEO of Triomics, a New York-based startup building oncology-specific AI agents that read the thousands of pages inside a cancer patient's chart so that clinicians don't have to. A chemical engineer trained at IIT Roorkee with a brief stint researching polymer gels in brain tissue at MIT, he started Triomics in 2021 with college friend Hrituraj Singh, went through Y Combinator's W21 batch, and by mid-2026 had raised $22 million in Series B financing led by Battery Ventures and deployed the platform at Memorial Sloan Kettering, Yale Cancer Center, and four of the top ten U.S. News cancer hospitals.

- **Role:** Co-Founder & CEO at Triomics
- **Organizations:** Triomics, Y Combinator (W21 alum), Massachusetts Institute of Technology (former), Indian Institute of Technology Roorkee (alum)
- **From:** New Delhi, India
- **Nationality:** Indian
- **Education:** B.Tech, Chemical Engineering, Indian Institute of Technology Roorkee, Biotech Researcher (research role), Massachusetts Institute of Technology
- **Known for:** Co-founded and scaled Triomics to serve four of the top ten U.S. News-ranked cancer hospitals, Raised $54M+ total across pre-seed, Series A ($15M, 2024) and Series B ($22M, 2026), Deployed at Memorial Sloan Kettering Cancer Center and Yale Cancer Center

## Career timeline

- **2019** — Joins MIT as a biotech researcher, working on polymer gels that expand inside brain tissue
- **2020** — Leaves MIT
- **2021** — Co-founds Triomics with IIT Roorkee friend Hrituraj Singh; joins Y Combinator's Winter 2021 batch
- **2024** — Triomics raises $15M Series A to automate cancer clinical trial matching
- **2025** — Memorial Sloan Kettering signs on to deploy Triomics' AI platform
- **2026** — Series B: $22M led by Battery Ventures; customer base 4x, ARR 10x year-over-year

## Achievements

- Co-founded and scaled Triomics to serve four of the top ten U.S. News-ranked cancer hospitals
- Raised $54M+ total across pre-seed, Series A ($15M, 2024) and Series B ($22M, 2026)
- Deployed at Memorial Sloan Kettering Cancer Center and Yale Cancer Center
- Grew ARR 10x and enterprise customer base 4x in the year leading up to Series B
- Y Combinator Winter 2021 alumnus

## Latest updates

- **2026-05** — Triomics announces $22M Series B led by Battery Ventures, with Nexus, Lightspeed, and Y Combinator participating.
- **2026-06** — Healthcare IT Today profiles Triomics' adoption across leading cancer centers.

## Links

- Website: https://triomics.com
- LinkedIn: https://www.linkedin.com/in/sarim-khan-triomics
- Twitter/X: https://twitter.com/Triomicsinc

---

Profile page: https://yespress.io/sarim-khan
Published by YesPress — https://yespress.io
Last updated: 2026-07-08